[Public Notice+] Cellivery Registers Patent in Japan for Parkinson's Disease Treatment New Drug

[Asia Economy Reporter Hyunseok Yoo] Cellivery announced on the 4th that its Parkinson's disease treatment drug candidate iCP-Parkin has successfully registered patents in Japan, following Australia and the European Union (EU).

Daewoong Cho, CEO of Cellivery, stated, "The Parkinson's disease treatment iCP-Parkin, for which the Japanese patent registration has been completed, is one of Cellivery's major new drug development pipelines," adding, "With the acquisition of the Japanese patent, we expect negotiations with Japanese pharmaceutical companies currently discussing licensing out (L/O) to gain momentum."

The pharmacological substance in vivo delivery technology TSDT enables cell-to-cell delivery and brain tissue penetration through continuous transfer between vascular endothelial cells. By delivering the pharmacological substance (Parkin protein for Parkinson's disease treatment) into the brain, it can exert therapeutic effects on Parkinson's disease. At the same time, it simultaneously solves the longstanding challenge of drug development caused by the blood-brain barrier, enabling the development of various brain disease treatments, according to the company.

A company representative emphasized, "Since iCP-Parkin has potential not only for Parkinson's disease but also as an anticancer and Alzheimer's disease treatment, we are conducting verification tests to expand indications, and we are confident this will increase the value of iCP-Parkin."

The Parkinson's disease treatment iCP-Parkin is currently undergoing aggressive candidate evaluations by multiple multinational pharmaceutical companies on the premise of licensing out (L/O). Additionally, the company has signed multiple contracts with contract research organizations (CROs) and contract manufacturing organizations (CMOs) in Germany, China, Japan, and the United States to produce non-clinical and clinical trial materials. Furthermore, the company explained that safety and efficacy evaluations are being conducted simultaneously with CROs in the United Kingdom, Finland, and Canada.

Parkinson's disease is a degenerative brain disorder caused by the selective loss of dopaminergic neurons (DA neurons), resulting in incomplete dopamine production and action, which reduces stimulation of the motor cortex. Pathologically, it is a motor disorder accompanied by impaired motor function that worsens over time. The incidence increases mainly with age, progresses slowly and gradually, and currently has no fundamental cure.

This content was produced with the assistance of AI translation services.